keynote 199 cohorts 4 & 5: enzalutamide and pembrolizumab for mcrpc
Published 4 years ago • 72 plays • Length 2:35Download video MP4
Download video MP3
Similar videos
-
3:18
keynote-199: an update on pembrolizumab for mcrpc
-
2:54
updated analysis of keynote-199: pembrolizumab for mcrpc previously treated with docetaxel
-
3:02
updates from keynote 57: pembrolizumab for patients with bladder cancer
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
3:57
pembrolizumab plus 5-fu and cisplatin for first-line treatment in...
-
4:20
keynote-604: pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-sta...
-
0:53
dr. freedland on real-world utility of enzalutamide in prostate cancer
-
0:50
dr. graff on the keynote-641 trial in mcrpc
-
2:17
enzalutamide for biochemically recurrent prostate cancer | nejm
-
1:02
dr. agarwal on the safety profile of enzalutamide/talazoparib in mcrpc
-
8:09
comparing apalutamide and enzalutamide in real-world treatment of mcspc
-
2:11
finding the best surgery for prostate cancer video
-
1:45
nci-connect clinic: why participate
-
1:55
awaiting key results for enzalutamide and apalutamide in nmcrpc
-
4:12
calgb 90601: comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urot...
-
2:10
holep - treatment for enlarged prostrate
-
12:40
09/12/2018 - closing panel: goldstein
-
5:46
priority reviews in bladder cancer and hcc, clinical hold lifted in myelofibrosis, and more
-
4:32
advanced prostate cancer part 5